Neumora Therapeutics, Inc. (NMRA)
Nasdaq: NMRA · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2021
Who owns Neumora Therapeutics, Inc.
As filed with the SECHolders of 5% or more
2
Kristina Burow holds 18.7% of Common Stock, $0.0001 par value, as its SCHEDULE 13D/A filed Apr 1, 2026 says.
Directors and officers
10
report now, of 13 people on the record since 2023. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 2 named at left.
Holders of 5% or moreshare of the class, as filed
Kristina Burow
SCHEDULE 13D/A · filed Apr 1, 2026 · Common Stock, $0.0001 par value · 20.7% in Oct 29, 2025
Paul L Berns
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock par value $0.0001 per share
Raymond Debbane
SCHEDULE 13G/A · filed May 4, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.4% in Feb 19, 2026
K2 HealthVentures Equity Trust LLC
SCHEDULE 13G/A · filed May 15, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 5.01% in Feb 17, 2026
Fmr LLC
SCHEDULE 13G/A · filed May 12, 2025 · COMMON STOCK · reported falling below 5%, from 5.4% in Jul 8, 2024
What NMRA reports owning in othersstakes of 5% or more, and other ties
Neumora Therapeutics, Inc. reports no stake in another company in the record.
Insider tradesForm 4
16sales
1purchases
2sales on a scheduled plan
4people selling
$1.1Msold, in dollars
$5.0Mbought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window7 of 32 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Aurora Daljit Singh | Title: Chief Operating and Development Officer | 13 | $1.0M | 1 | 0 | $0 |
| Burow Kristina | director | 0 | $0 | 0 | 1 | $5.0M |
| Arch Venture Partners Viii, LLC | 10% owner | 0 | $0 | 0 | 1 | $5.0M |
| Arch Venture Partners Xii, LLC | 10% owner | 0 | $0 | 0 | 1 | $5.0M |
| Pinto Joshua | President & CEO | 1 | $0 | 0 | 0 | $0 |
| Berns Paul L | Title: Executive Chair of the Board | 1 | $0 | 0 | 0 | $0 |
| Milligan Michael Lee | Title: Chief Financial Officer & Principal Accounting Officer | 1 | $0 | 1 | 0 | $0 |